{
    "nctId": "NCT00107393",
    "briefTitle": "Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Median survival and 2-year survival rate as measured by the Kaplan-Meier method 2 years after completion of study treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Metastatic disease\n\n    * Patients with only bone metastases are not eligible\n* Refractory disease, defined as disease progression, drug-related adverse reaction, or disease relapse during or within 12 months after completion of paclitaxel or docetaxel AND doxorubicin or epirubicin administered in the neoadjuvant, adjuvant, or metastatic setting\n\n  * Total neoadjuvant or adjuvant taxane dose \\> 700 mg/m\\^2 for paclitaxel or \\> 240 mg/m\\^2 for docetaxel\n  * Total taxane dose \\> 350 mg/m\\^2 for paclitaxel or \\> 120 mg/m\\^2 for docetaxel in the metastatic setting\n  * Total neoadjuvant or adjuvant anthracycline dose \\> 240 mg/m\\^2 for doxorubicin or epirubicin\n  * Total anthracycline dose \\> 120 mg/m\\^2 for doxorubicin or epirubicin in the metastatic setting\n* HER2/neu overexpression\n\n  * 3+ by immunohistochemistry or positive by fluorescence in situ hybridization\n* No symptomatic brain metastases\n* No pleural or pericardial effusion or ascites\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 20 to 75\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 3 months\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 9.0 g/dL\n\nHepatic\n\n* SGOT or SGPT \u2264 2.0 times upper limit of normal (ULN) (\\< 3.0 times ULN for patients with liver metastases)\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Bilirubin \u2264 1.5 mg/dL\n\nRenal\n\n* Creatinine \u2264 1.2 mg/dL\n\nCardiovascular\n\n* LVEF \\> 50%\n\nPulmonary\n\n* No interstitial pneumonia with pulmonary fibrosis\n\nOther\n\n* No history of hypersensitivity reactions\n* No serious, uncontrolled infection\n* No other malignancy\n* Not pregnant or nursing\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Prior trastuzumab (Herceptin\u00ae) for metastatic disease allowed\n\nChemotherapy\n\n* See Disease Characteristics\n* No prior capecitabine\n* At least 2 weeks since prior antimetabolites for metastatic disease\n* At least 4 weeks since prior alkylating agents, carcinostatic antibiotics, or other carcinostatic agents\n\nEndocrine therapy\n\n* At least 4 weeks since prior goserelin or leuprolide for metastatic disease\n* At least 2 weeks since prior oral endocrine agents for metastatic disease\n* No concurrent endocrine therapy\n\nRadiotherapy\n\n* No prior radiotherapy to target lesions\n* At least 4 weeks since prior radiotherapy\n* No concurrent radiotherapy, including radiotherapy for brain metastases\n\nSurgery\n\n* Not specified\n\nOther\n\n* Concurrent bisphosphonates for bone metastases allowed",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}